HC Wainwright Says That MannKind (NASDAQ:MNKD) Has $7 Stock Target

Leslie Hanson
October 12, 2017

If the $5.85 price target is reached, the company will be worth $29.15M more. Through this figure traders can analyze that MNKD show whether or not a stock now most active and standing in buying side or sell side. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

Technical traders may be staring at recent indicator levels on shares of MannKind Corporation (MNKD).

MannKind Corporation (NASDAQ:MNKD) has shown an EPS growth of 17.20% in the last 5 years and sales growth of 411.30% for the same year while for the next 5 years; the EPS growth estimates 26.80%.Along with this Sales growth yoy (quarter over quarter) was considered as -. It has underperformed by 91.97% the S&P500. As of the last earnings report the EPS was $1.33 and is expected to be $-0.94 for the current year with 104,683,000 shares now outstanding. During the same period in the previous year, the firm earned $0.08 earnings per share.

Taking a closer look into the volatility on shares of MannKind Corporation (NASDAQ:MNKD), we notice that the stock is 93.21% off of the 20-Day Simple Moving Average. The firm has made a decision to set a Buy rating along with a $7.00, adding 4.95 % to the target. Therefore 43% are positive. The company burned through $23 million in cash during the third quarter while managing to sell (on a net basis) just $1.8 million to $2.2 million of Afrezza, according to preliminary financial results disclosed Wednesday. The stock of MannKind Corporation (NASDAQ:MNKD) earned "Underweight" rating by Piper Jaffray on Wednesday, September 9.

MannKind Corporation has a consensus hold rating from 2 Wall Street analysts, and the number of shares now sold short amount to at least 31.07% of shares outstanding. As per Wednesday, November 4, the company rating was downgraded by RBC Capital Markets.

In a research note sent to clients and investors on Tuesday, 10 October, equity research analysts at H.C. Wainwright started coverage for Mannkind Corporation (NDAQ:MNKD) shares. The rating was maintained by RBC Capital Markets with "Underperform" on Tuesday, May 10. The company was downgraded on Friday, August 28 by Vetr. The rating was maintained by RBC Capital Markets on Monday, August 3 with "Outperform". The firm has "Buy" rating given on Friday, October 6 by Maxim Group. The stock has "Neutral" rating by Griffin Securities on Monday, November 16. More interesting news about MannKind Corporation (NASDAQ:MNKD) were released by: Seekingalpha.com and their article: "MannKind: FDA Label Decision Is Almost Here" published on September 27, 2017 as well as Seekingalpha.com's news article titled: "MannKind Is In A Race It Can't Win" with publication date: October 06, 2017.

Consequently Mannkind Corporation (NASDAQ:MNKD)'s weekly and monthly volatility is 32.99%, 15.95% respectively. The company has market cap of $583.00 million. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. The company's P/E (price to earnings) ratio is 4.97 and Forward P/E ratio of 0.

Other reports by Iphone Fresh

Discuss This Article